Lymphogranuloma venereum BY PCR

The Lymphogranuloma Venereum BY PCR is a molecular diagnostic test that detects DNA from Chlamydia trachomatis L‑serovars (L1–L3), the bacteria responsible for LGV. Using a nucleic acid amplification (PCR/NAAT) method on samples such as genital or rectal swabs or first‑catch urine, the test provides highly sensitive qualitative results (positive/negative) to confirm infection.

This at‑home kit is designed for discreet collection with secure transport to UAE‑licensed laboratories for analysis and confidential electronic reporting. It is recommended for symptomatic individuals (ulcers, proctitis, swollen inguinal nodes), people with recent high‑risk sexual exposure, and contacts of confirmed cases; positive results enable timely treatment and public health contact tracing, while negatives should be interpreted with clinical correlation and, if needed, repeat testing.

• Chlamydia trachomatis L‑serovars (L1–L3) DNA
• LGV‑specific PCR result (Positive / Negative)
• Specimen type: Genital or Rectal Swab
• Specimen type: First‑catch Urine (where applicable)
• Test methodology: Real‑time PCR (NAAT)

• Genital or rectal ulcers, bumps, or persistent sores
• Painful or swollen inguinal (groin) lymph nodes
• Symptoms of proctitis: rectal pain, bleeding, discharge, tenesmus
• Recent unprotected anal or genital sex with a new or multiple partners
• Identified contact of a confirmed LGV case or persistent STI symptoms despite treatment

• Discreet at‑home sample collection with clear instructions
• High sensitivity PCR testing for specific LGV serovars
• Analysis performed in UAE‑licensed laboratories with confidential reporting
• Rapid, actionable results to guide timely antibiotic treatment and contact tracing
• Suitable for screening high‑risk individuals and symptomatic patients

• At‑home genital or rectal swab kit or first‑catch urine sample provided
• Avoid sexual intercourse, douching, or intravaginal products for 24–48 hours before collection
• If possible, do not take antibiotics for at least 14 days prior to testing (discuss with your clinician)
• Available for individuals aged 18+ residing in the UAE; samples processed by UAE‑licensed labs with secure electronic results